| Literature DB >> 33322363 |
Fotios Papadopoulos1, Rafaela Isihou1, George A Alexiou1, Thomas Tsalios2, Evrysthenis Vartholomatos1, Georgios S Markopoulos3, Chrissa Sioka1, Pericles Tsekeris4, Athanasios P Kyritsis1, Vasiliki Galani2.
Abstract
Although several antipsychotic drugs have been shown to possess anticancer activities, haloperidol, a "first-generation" antipsychotic drug, has not been extensively evaluated for potential antineoplastic properties. The aim of this study was to investigate the antitumoral effects of haloperidol in glioblastoma (GBM) U87, U251 and T98 cell lines, and the effects of combined treatment with temozolomide (TMZ) and/or radiotherapy, using 4 Gy of irradiation. The viability and proliferation of the cells were evaluated with trypan blue exclusion assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis, using the annexin-propidium iodide (PI), and cell cycle, cluster of differentiation (CD) expression and caspase-8 activation were measured using flow cytometry. Treatment with haloperidol significantly reduced cell viability in U87, U251 and T98 GBM cell lines. Haloperidol induced apoptosis in a dose-dependent manner, inhibited cell migration and produced an alteration in the expression of CD24/CD44. The additional effect of haloperidol, combined with temozolomide and radiation therapy, increased tumor cell death. Haloperidol was observed to induce apoptosis and to increase caspase-8 activation. In conclusion, haloperidol may represent an innovative strategy for the treatment of GBM and further studies are warranted in glioma xenograft models and other malignancies.Entities:
Keywords: antipsychotic; apoptosis; glioblastoma cells; haloperidol
Year: 2020 PMID: 33322363 PMCID: PMC7763579 DOI: 10.3390/biomedicines8120595
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059